Charles River Laboratories International, Inc. (NYSE:CRL) will post its quarterly earnings results before the market opens on Tuesday, August 1st. Analysts expect Charles River Laboratories International to post earnings of $1.22 per share for the quarter. Charles River Laboratories International has set its FY17 guidance at $5.00-5.15 EPS.

Charles River Laboratories International (NYSE:CRL) last released its earnings results on Wednesday, May 10th. The medical research company reported $1.29 earnings per share for the quarter, beating analysts’ consensus estimates of $1.14 by $0.15. Charles River Laboratories International had a return on equity of 27.46% and a net margin of 9.28%. The company had revenue of $445.80 million during the quarter, compared to analyst estimates of $437.04 million. During the same quarter in the previous year, the company posted $0.98 EPS. Charles River Laboratories International’s revenue for the quarter was up 25.6% on a year-over-year basis. On average, analysts expect Charles River Laboratories International to post $5.1 EPS for the current fiscal year and $5.63 EPS for the next fiscal year.

Shares of Charles River Laboratories International, Inc. (NYSE CRL) opened at 101.72 on Tuesday. The company has a market cap of $4.85 billion, a price-to-earnings ratio of 29.77 and a beta of 1.03. The stock has a 50 day moving average price of $98.59 and a 200-day moving average price of $90.03. Charles River Laboratories International, Inc. has a 1-year low of $67.20 and a 1-year high of $102.32.

Charles River Laboratories International declared that its Board of Directors has approved a share buyback plan on Wednesday, May 10th that allows the company to repurchase $150.00 million in shares. This repurchase authorization allows the medical research company to buy shares of its stock through open market purchases. Shares repurchase plans are generally an indication that the company’s management believes its shares are undervalued.

ILLEGAL ACTIVITY WARNING: “Charles River Laboratories International, Inc. (NYSE:CRL) Scheduled to Post Earnings on Tuesday” was originally published by American Banking News and is owned by of American Banking News. If you are viewing this piece of content on another site, it was illegally stolen and republished in violation of United States and international trademark & copyright legislation. The original version of this piece of content can be read at https://www.americanbankingnews.com/2017/07/25/charles-river-laboratories-international-inc-nysecrl-scheduled-to-post-earnings-on-tuesday.html.

A number of brokerages recently commented on CRL. Jefferies Group LLC reaffirmed a “buy” rating and issued a $121.00 price target on shares of Charles River Laboratories International in a report on Friday, June 30th. Zacks Investment Research raised shares of Charles River Laboratories International from a “hold” rating to a “buy” rating and set a $111.00 price objective for the company in a research note on Wednesday, July 12th. Citigroup Inc. reissued a “neutral” rating and issued a $104.00 price objective (up previously from $91.00) on shares of Charles River Laboratories International in a research note on Wednesday, June 28th. Barclays PLC reissued a “hold” rating and issued a $102.00 price objective on shares of Charles River Laboratories International in a research note on Wednesday, July 19th. Finally, BidaskClub raised shares of Charles River Laboratories International from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, June 20th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating, four have given a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $97.06.

In other news, insider David Ross Smith sold 945 shares of the firm’s stock in a transaction that occurred on Thursday, June 8th. The shares were sold at an average price of $95.00, for a total transaction of $89,775.00. Following the transaction, the insider now directly owns 14,203 shares of the company’s stock, valued at $1,349,285. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director George Massaro sold 1,130 shares of the firm’s stock in a transaction that occurred on Friday, May 12th. The stock was sold at an average price of $88.30, for a total transaction of $99,779.00. Following the transaction, the director now directly owns 15,831 shares in the company, valued at $1,397,877.30. The disclosure for this sale can be found here. In the last three months, insiders sold 80,499 shares of company stock valued at $7,946,191. 2.20% of the stock is owned by insiders.

About Charles River Laboratories International

Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.

Earnings History for Charles River Laboratories International (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.